Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma.
Saved in:
| Title: | Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma. |
|---|---|
| Authors: | Borgers JSW; Medical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands., van Wesemael TJ; Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands., Gelderman KA; Sanquin Diagnostic Services, Amsterdam, Noord-Holland, Netherlands., Rispens T; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam, Noord-Holland, UK., Verdegaal EME; Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands., Moes DJAR; Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands., Korse CM; Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, Netherlands., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands., Welters MJP; Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Netherlands., van der Burg SH; Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Netherlands., van Houdt WJ; Surgical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands., van Thienen JV; Medical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands., Haanen JBAG; Medical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands j.haanen@nki.nl.; Department of Medical Oncology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands., van der Woude D; Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Jun 30; Vol. 12 (6). Date of Electronic Publication: 2024 Jun 30. |
| Publication Type: | Journal Article; Multicenter Study |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
